Lexicon Pharmaceuticals | LXRX - Ordinary Share Capital


Lexicon Pharmaceuticals reported $363.47M in Ordinary Share Capital for its fiscal quarter ending in December of 2025.





Ordinary Share Capital Change Date
Abbott USD 1.74B 23.39B Sep/2025
Acadia Pharmaceuticals USD 169.18M 470K Dec/2025
Agios Pharmaceuticals USD 59.34M 892K Mar/2026
Akebia Therapeutics USD 265.42M 199K Dec/2025
Alnylam Pharmaceuticals USD 133.44M 1.07M Mar/2026
AstraZeneca USD 1.55B 73K Mar/2026
BioMarin Pharmaceutical USD 193.27M 969K Mar/2026
Coherus Biosciences USD 121.16M 4.92M Dec/2025
Eli Lilly USD 943.5M 3.33M Mar/2026
Esperion Therapeutics USD 245.22M 39.79M Dec/2025
Halozyme Therapeutics USD 118.52M 741K Mar/2026
Illumina USD 151.91M 893K Mar/2026
Insmed USD 216.52M 2.27M Mar/2026
Ironwood Pharmaceuticals USD 160K 0 Dec/2024
J&J USD 2.41B 1.74M Dec/2025
Lexicon Pharmaceuticals USD 363.47M 67K Dec/2025
MacroGenics USD 63.56M 241K Mar/2026
MannKind USD 308.91M 1.07M Mar/2026
Merck USD 2.47B 12.72M Dec/2025
Moderna USD 391M 2M Sep/2025
Novartis USD 1.91B 60K Mar/2026
PTC Therapeutics USD 81.47M 1.54M Dec/2025
Puma Biotechnology USD 5K 0 Jun/2024
Sarepta Therapeutics USD 105.57M 607K Mar/2026
Thermo Fisher Scientific USD 371.62M 4.09M Mar/2026
Ultragenyx Pharmaceutical USD 98.3M 1.7M Mar/2026
United Therapeutics USD 42.16M 1.49M Mar/2026
Vanda Pharmaceuticals USD 58K 0 Dec/2024